Analyst consensus rating
Orchestra BioMed Holdings Analyst Rating: none
OBIO is rated none by 6 analysts with a $12.33 target. As of 2026-08-29.
Direct answer
Orchestra BioMed Holdings's consensus rating is none.
6 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $12.33.
Forecast evidence checked August 29, 2026.
Get free Orchestra BioMed Holdings email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $5.19
- Average price target
- $12.33
- High price target
- $20.00
- Low price target
- $9.00
- Low target gap
- +73.6%
- Target upside
- +137.9%
- High target gap
- +285.7%
- Target range width
- 212.2%
- Consensus rating
- none
- Analysts
- 6
- Evidence date
- August 29, 2026
- Valid through
- September 5, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Orchestra BioMed Holdings?
Orchestra BioMed Holdings has a verified none consensus. The same dataset has an average price target of $12.33.
How far are Orchestra BioMed Holdings's low and high targets from the recorded price?
The low target implies +73.6%, while the high target implies +285.7%.
How many analysts are included in Orchestra BioMed Holdings's consensus?
The verified consensus includes 6 analysts.
How is Orchestra BioMed Holdings's target upside or downside calculated?
The average target of $12.33 is divided by the recorded price of $5.19, then one is subtracted to produce +137.9%. This does not guarantee a future return.
When was Orchestra BioMed Holdings's analyst forecast verified?
The data was verified on 2026-08-29. The dataset is valid through 2026-09-05.